STAMBP

Across TCGA pan-cancer cohorts, STAMBP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STAMBP data layer compared with 30 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher STAMBP mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated STAMBP expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where STAMBP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	0.681	0.946	.011	16	view →
LUAD	DFS	Quartile	All	0.377	0.817	<.001	15	view →
HNSC	DFS	Tertile	II,III,IV	1.000	0.870	.006	13	view →
PDAC	OS	Tertile	II,III,IV	0.729	0.908	.006	9	view →
GBM	OS	Median	All	0.714	0.915	.005	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STAMBP–CCRCC (OS)

Open the CCRCC breakdown →